Routine clinical follow-up for distant metastatic disease among women with early stage breast cancer is of uncertain clinical benefit.
In order to evaluate current practice patterns, we administered a mailed survey to a stratified random sample of physician members of the American Society of Clinical Oncology (ASCO) (N=435).
The survey assessed the frequency and motivation for ordering follow-up medical tests in asymptomatic postmenopausal women with stage I or II breast cancer.
The response rate was 55%, distributed as 39% radiation oncologists, 32% medical oncologists, and 29% surgeons.
In the first year after treatment, physicians performed, on average, one physical examination every 3 months, one blood panel (CBC, alkaline phosphatase and liver function tests) every 4 months, and one chest radiograph every 9 months.
Mots-clés Pascal : Tumeur maligne, Glande mammaire, Glande mammaire pathologie, Stade précoce, Surveillance, Dépistage, Métastase, Homme, Femelle, Postménopause, Médecin, Etats Unis, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Malignant tumor, Mammary gland, Mammary gland diseases, Early stage, Surveillance, Medical screening, Metastasis, Human, Female, Postmenopause, Physician, United States, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0061939
Code Inist : 002B20E02. Création : 199406.